The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosidase (GCase), an enzyme required for the break-down of glucocerebroside thus causing a build-up in areas like the spleen, liver, and bone marrow.
With an equal prevalence in males and females, the overall frequency of Gaucher Disease is approximately 1 in 50,000 to 1 in 100,000 live births.
The newsletter by DelveInsight offers a crisp overview of the indication, its subtypes and symptoms. It also brings into focus the epidemiological trends segmented into geographies in the 7MM, ethnicity, gender, total and diagnosed cases.
As per DelveInsight assessments, the market size of Gaucher disease is anticipated to increase for the study period, 2017–2030. The newsletter aims to help its clients and readers to gain insights into market trends and the pipeline Upcoming Conferences
that shall veer the Gaucher disease market in a positive direction.
For rich insights into Gaucher disease market landscape fill the form and get the newsletter rights into your inbox.
Escape the hassle of filling the forms every time by subscribing to our emailer's list and get all the updates and trends in the pharma industry into your inbox.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Market insights
- Pipeline drugs
- Latest News
- R&D in the field
- Support from International organizations
- Upcoming Conferences